Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial
I Romera Martínez, C Avendaño‐Solá… - Vox …, 2024 - Wiley Online Library
Abstract Background and Objectives The efficacy of COVID‐19 convalescent plasma (CP)
associates with high titres of antibodies. ConPlas‐19 clinical trial showed that CP reduces …
associates with high titres of antibodies. ConPlas‐19 clinical trial showed that CP reduces …
Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from august to December 2020
G Davis, AJ York, WC Bacon, SC Lin, MM McNeal… - Plos one, 2021 - journals.plos.org
The world is currently in a pandemic of COVID-19 (Coronavirus disease-2019) caused by a
novel positive-sense, single-stranded RNA β-coronavirus referred to as SARS-CoV-2. Here …
novel positive-sense, single-stranded RNA β-coronavirus referred to as SARS-CoV-2. Here …
Assessing Seroprevalence of SARS-CoV-2 Antibodies Among US College Students after School Reopening
SE Feeder, T Ratishvili, BL Carlson, DE Grill… - medRxiv, 2024 - medrxiv.org
Objective This study assessed the seroprevalence of SARS-CoV-2 antibodies at two
timepoints to evaluate the effectiveness of COVID-19 precautions in two colleges …
timepoints to evaluate the effectiveness of COVID-19 precautions in two colleges …
COVID-19 antibody detection and assay performance using red cell agglutination
Red cells can be labeled with peptides from the SARS-CoV-2 spike protein (C-19
kodecytes) and used as reagent cells for serologic screening of SARS-CoV-2 antibodies …
kodecytes) and used as reagent cells for serologic screening of SARS-CoV-2 antibodies …